首页> 外文学位 >Identification of differentially expressed genes and activation of the TGF-beta signal transduction pathway in mammary carcinomas treated with the anticancer monoterpenes limonene and perillyl alcohol.
【24h】

Identification of differentially expressed genes and activation of the TGF-beta signal transduction pathway in mammary carcinomas treated with the anticancer monoterpenes limonene and perillyl alcohol.

机译:在用抗癌单萜柠檬烯和紫苏醇治疗的乳腺癌中鉴定差异表达的基因并激活TGF-β信号转导途径。

获取原文
获取原文并翻译 | 示例

摘要

The monoterpenes limonene (LIM) and perillyl alcohol (POH) are effective chemoprevantitive and chemotherapeutic agents currently in clinical trials.;Using a newly developed methodology, subtractive display, numerous differentially expressed genes were identified in dietary 10% LIM-treated, DMBA-induced rat mammary carcinomas undergoing regression compared to control carcinomas. The subtractive display methodology combined a polymerase chain reaction-based subtractive hybridization procedure with the ability to selectively amplify and display subpopulations of subtracted cDNA for their subsequent identification. Involvement of the transforming growth factor beta (TGF-beta) signaling pathway in tumor regression was suggested by the identification of mannose 6-phosphate/insulin-like growth factor II receptor (M6P/IGF2R) and TGF-beta type II receptor (TbetaIIR) as induced genes. Involvement of apoptosis in tumor regression was suggested by identification of the mammary gland marker of programmed cell death, lipocortin 1, also termed annexin I, as an induced gene. Consistent with differentiation in tumor regression, YWK-II was induced and neuroligin 1 was repressed.;TGF-beta signaling, and its potential downstream effects on cellular proliferation and death, were investigated in 2% POH-treated regressing mammary carcinomas. Using nuclease protection assays (NPAs) to study RNA expression, it was found that TGF-beta signaling components were induced and temporally regulated: first, transient c-jun and c-fos; second, TGF-beta1; third, M6P/IGF2R, TbetaIIR, and TGF-beta type I receptor (TbetaIR); and fourth, smad3. Immunohistochemistry confirmed that TGF-beta1, M6P/IGF2R, TbetaIIR, TbetaIR, and Smad2/Smad3 were upregulated and colocalized in epithelium. Smad2/Smad3 exhibited nuclear localization, indicating activation of TGF-beta signaling in POH-treated carcinomas. A subpopulation of Smad2/Smad3 nuclei colocalized with a subpopulation of apoptotic nuclei. NPAs demonstrated that the cell cycle- and apoptosis-related genes p21Cip1/WAF1, bax, bad, and annexin I were induced, cyclin E and CDK2 were repressed; and bcl-2 and p53 were unchanged. As demonstrated by terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling and in vivo bromodeoxyuridine labeling, POH induced apoptosis within 48 h of treatment, before the induction of cytostasis during active carcinoma regression. Importantly, all of POH's anticancer activities were specific to mammary carcinomas compared to normal mammary gland and thus may explain in part the lack of toxicity associated with monoterpene therapy and its high therapeutic efficacy in vivo.
机译:单萜柠檬烯(LIM)和紫苏醇(POH)是目前在临床试验中有效的化学预防剂和化学治疗剂;使用一种新开发的方法,减性显示法,在10%的LIM处理,DMBA诱导的饮食中鉴定出许多差异表达的基因与对照癌相比,大鼠乳腺癌正在退化。消减展示方法结合了基于聚合酶链反应的消减杂交程序,能够选择性地扩增和显示被消减cDNA的亚群以用于随后的鉴定。通过鉴定甘露糖6-磷酸/胰岛素样生长因子II受体(M6P / IGF2R)和TGF-βII型受体(TbetaIIR),表明转化生长因子β(TGF-beta)信号通路参与了肿瘤消退作为诱导基因。通过鉴定程序性细胞死亡的乳腺标记物脂皮质激素1,也称为膜联蛋白I,作为诱导基因,提示凋亡参与肿瘤消退。与肿瘤消退中的分化一致,诱导了YWK-II并抑制了神经胶蛋白1。在2%POH治疗的退行性乳腺癌中研究了TGF-β信号传导及其对细胞增殖和死亡的潜在下游影响。使用核酸酶保护分析(NPA)研究RNA表达,发现TGF-β信号转导成分被诱导并受到时间调控:首先是瞬时c-jun和c-fos;其次是c-fos。第二,TGF-beta1;第三,M6P / IGF2R,TbetaIIR和TGF-beta I型受体(TbetaIR);第四,smad3。免疫组织化学证实,TGF-β1,M6P / IGF2R,TbetaIIR,TbetaIR和Smad2 / Smad3在上皮细胞中上调并共定位。 Smad2 / Smad3表现出核定位,表明在POH治疗的癌症中TGF-beta信号的激活。 Smad2 / Smad3核的亚群与凋亡核的亚群共定位。 NPAs证实,诱导了细胞周期和凋亡相关基因p21Cip1 / WAF1,bax,bad和Annexin I,抑制了cyclin E和CDK2。 bcl-2和p53不变。如末端脱氧核苷酸转移酶介导的dUTP缺口末端标记和体内溴脱氧尿苷标记所证明的,在活跃的癌症消退期间,在诱导细胞停滞之前,POH在治疗后48小时内诱导了细胞凋亡。重要的是,与正常的乳腺相比,POH的所有抗癌活性都是针对乳癌的,因此可以部分解释单萜治疗缺乏毒性及其体内高治疗功效。

著录项

  • 作者

    Ariazi, Eric Anthony.;

  • 作者单位

    The University of Wisconsin - Madison.;

  • 授予单位 The University of Wisconsin - Madison.;
  • 学科 Health Sciences Oncology.;Health Sciences Pharmacology.;Biology Molecular.
  • 学位 Ph.D.
  • 年度 1998
  • 页码 246 p.
  • 总页数 246
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号